Advertisement

The Study of Chiral Cardiovascular Drugs: Analytical Approaches and Some Pharmacological Consequences

  • Richard L. Lalonde
  • Michael B. Bottorff
  • Irving W. Wainer
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 18 A)

Abstract

For chiral CV* drugs, which are administered as racemates, differences between the stereoisomers in pharmacological action have long been recognized. The difficult task of ascertaining the fate of each isomer has been eased by the development of HPLC methodology with CSP’s. This article deals with analytical approaches and, in outline†, pharmacological stereoselectivity aspects for propranolol, labetalol, disopyramide and verapamil as examples of chiral CV drugs for which information on plasma levels is clinically important.

Keywords

Essential Tremor Antiarrhythmic Agent Racemic Mixture Liver Blood Flow Enantiomeric Pair 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviation

CV

cardiovascular

CSP

chiral stationary phase [OD: see text]

HDA

homochiral derivatizing agent

TPC

N-trifluoroacetyl-l-prolyl chloride.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frey, W. (1918) Wien. Klin, Wochenschr. 55, 849–853.Google Scholar
  2. 2.
    White, N.J., Looareesuman, S. & Warrell, D.A. (1983) J. Cardiovasc. Pharmacol. 5, 173–175.CrossRefGoogle Scholar
  3. 3.
    Alexander, F., Gold, H. & Katz, L.N. (1947) Pharmacol. Exp. Ther. 90, 191–201.Google Scholar
  4. 4.
    Nies, A.S., Evans, G.H. & Shand, D.G. (1973) Am. Heart J. 85, 97–102.CrossRefGoogle Scholar
  5. 5.
    Wainer, I.W. (1986) in Bioactive Analytes, including CNS Drugs, Peptides and Enantiomers [Vol. 16, this series] (Reid, E., Scales, B. & Wilson, I.D., eds.), Plenum, New York, pp. 243–257.CrossRefGoogle Scholar
  6. 6.
    Lindner, W. & Petersson, K. (1985) in Liquid Chromatography in Pharmaceutical Development: An Introduction (Wainer, I.W., ed.), Aster Publg. Corp., Springfield, OR, pp. 63–131.Google Scholar
  7. 7.
    Wainer, I.W. (1987) Trends Anal. Chem. 6, 125–134.CrossRefGoogle Scholar
  8. 8.
    Williams, K., & Lee, E. (1978) Drugs 30, 333–354.CrossRefGoogle Scholar
  9. 9.
    Weiner, N. (1985) in The Pharmacological Basis of Therapeutics (Gilman, A.G., Goodman, L.S., Rall, T.W. & Murad, F., eds.), MacMillan, New York, pp. 176–210.Google Scholar
  10. 10.
    Barrett, A.M. & Cullum, V.A. (1984) Br. J. Pharmacol. 34, 43–55.CrossRefGoogle Scholar
  11. 11.
    Larsen, T.A. & Teravainen, H. (1982) Acta Neurol. Scand. 66, 289–294.CrossRefGoogle Scholar
  12. 12.
    Silber, B., Holford, N.H.G. & Riegelman, S. (1982) J. Pharm. Sci. 71, 699–704.CrossRefGoogle Scholar
  13. 13.
    Olanoff, L.S., Walle, T., Cowart, T.D., Walle, U.K., Oexmann, M.J. & Conradi, E.C. (1986) Clin. Pharmacol. Ther. 40, 408–414.CrossRefGoogle Scholar
  14. 14.
    Bai, S.A., Wilson, M.J., Walle, U.K. & Walle, T. (1983) J. Pharmacol. Exp. Ther. 227, 360–364.Google Scholar
  15. 15.
    Silber, B. & Riegelman, S. (1980) J. Pharmacol. Exp. Ther. 172, 643–648.Google Scholar
  16. 16.
    Hermansson, J. & von Bahr, C. (1980) J. Chromatog. 221, 109–117.Google Scholar
  17. 17.
    Hermansson, J. (1982) Suecica 19, 11–20.Google Scholar
  18. 18.
    Walle, T., Christ, D.D., Walle, U.K. & Wilson, M.J. (1985) J. Chromatog. 341, 213–216.Google Scholar
  19. 19.
    Krull, I.S. (1977) in Advances in Chromatography, Vol. 16 (Giddings, J. C., Grushka, E., Cazes, J. & Brown, P.R., eds.), Lippincott, Philadelphia, p. 146.Google Scholar
  20. 20.
    Pirkle, W.H., Finn, J.M., Schreiner, J.L. & Hamper, B.C. (1981) J. Am. Chem. Soc. 103, 3694–3696.CrossRefGoogle Scholar
  21. 21.
    Wainer, I.W., Doyle, T.D., Donn, K.H. & Powell, J.R. (1984) J. Chromatog. 306, 405–411.Google Scholar
  22. 22.
    Donn, K.H., Powell, J.R. & Wainer, I.W. (1985) Clin. Pharmacol. Ther, 37, 191.Google Scholar
  23. 23.
    Armstrong, D.W., Ward, T.J., Armstrong, R.D. & Bessley, T.E. (1986) Science 232, 1131–1135.CrossRefGoogle Scholar
  24. 24.
    Hermansson, J. (1985) J. Chromatog. 325, 379–384.CrossRefGoogle Scholar
  25. 25.
    Schill, G., Wainer, I.W. & Barkan, S.A. (1986) J. Chromatog. 365, 73–88.CrossRefGoogle Scholar
  26. 26.
    Okamoto, Y. Kawashima, M. & Aburatani, R. (1986) Chem. Lett., 1237–1240.Google Scholar
  27. 27.
    Straka, R.J., Lalonde, R.L. & Wainer, I.W. (1988) Pharmaceut. Res., in press.Google Scholar
  28. 28.
    Sybertz, E.J., Sabin, C.S., Pula, K.K., Vliet, G.V., Glennon, J., Gold, E.H. & Baum, T. (1981) J. Pharmacol. Exp. Ther. 218, 435–443.Google Scholar
  29. 29.
    Brittain, R.T., Drew, G.M. & Levy, G.P. (1982) Br. J. Pharmacol. 77, 105–114.CrossRefGoogle Scholar
  30. 30.
    Richards, D.A., Maconochie, J.G., Bland, P.E., Hopkins, R., Woodings, E.P. & Martin, L.E. (1977) Eur. J. Clin. Pharmacol. 11, 85–90.CrossRefGoogle Scholar
  31. 31.
    Pollick, C, Giacomini, K.M., Blaschke, T.F., Nelson, W.L., Turner-Taniyasu, K., Briskin, V. & Popp, R.L. (1982) Circulation 66, 447–453.CrossRefGoogle Scholar
  32. 32.
    Siddoway, L.A. & Woosley, R.L. (1986) Clin. Pharmacokin. 11, 214–222.CrossRefGoogle Scholar
  33. 33.
    Lima, J.J., Boudoulas, H. & Shields, B.J. (1985) Drug Metab. Dispos. 13, 572–577.Google Scholar
  34. 34.
    Giacomini, K.M., Nelson, W.L., Pershe, R.A., Valdiviesco, L., Turner-Taniyasu, K. & Blaschke, T.F. (1986) J. Pharmacokin. Biopharm. 14, 335–356.CrossRefGoogle Scholar
  35. 35.
    Hermansson, J. & Eriksson, M. (1984) J. Chromatog. 336, 321–328.Google Scholar
  36. 36.
    Ferry, D.R., Glossman, H. & Kaumann, A.J. (1985) Br. J. Pharmacol. 84, 811–824.CrossRefGoogle Scholar
  37. 37.
    Giacomini, J.C., Nelson, W.L., Theodore, L., Wong, F.M., Rood, D. & Giacomini, K.M. (1985) J. Cardiovasc. Pharmacol. 37, 469–475.CrossRefGoogle Scholar
  38. 38.
    Echizen, H., Vogelgesang, B. & Eichelbaum, M. (1985) Clin. Pharmacol. Ther. 38, 71–76.CrossRefGoogle Scholar
  39. 39.
    Vogelgesang, B., Echizen, H., Schmidt, E. & Eichelbaum, M. (1984) Br. J. Clin. Pharmacol. 18, 733–740.CrossRefGoogle Scholar
  40. 40.
    Eichelbaum, M., Mikus, G. & Vogelgesand, B. (1984) Br. J. Clin. Pharmacol. 17, 453–458.CrossRefGoogle Scholar
  41. 41.
    Wainer, I.W. & Alembik, M.C. (1987) in Chromatographic Chiral Separations (Crane, L. & Zief, M., eds.), Dekker, New York, pp. 355–387.Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Richard L. Lalonde
    • 1
  • Michael B. Bottorff
    • 1
  • Irving W. Wainer
    • 1
    • 2
  1. 1.Department of Clinical PharmacyUniversity of Tennessee, MemphisMemphisUSA
  2. 2.Pharmaceutical DivisionSt. Jude Children’s Research HospitalMemphisUSA

Personalised recommendations